Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction

• Status: Unknown status
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate whether the depth of anesthesia with propofol affects the incidence of early postoperative cognitive dysfunction

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xiangya Hospital of Central South University
• Treatments: Anesthetics; Propofol

Criteria

Inclusion Criteria:

• Written informed consent provided by legal guardians or patients

• Male or female patients between 50 and 70 years of age.

• ASA physical status I or II patients.

• Education Years of patients are more than 6 years.

• The operation going to be received is the first operation in patient's life (a second operation was a risk factor for early post- operative cognitive dysfunction);

• The operation going to be received is presenting for a moderate surgery, such as pulmonary lobectomy, subtotal gastrectomy, prostatectomy and so on.

Exclusion Criteria:

• The patient has the history of neurologic or mental disease.

• The patient has renal dysfunction, serum creatinine >177 mmol/L.

• The patient has an active liver disease.

• The patient has cardiac dysfunction.

• The patient has pulmonary dysfunction.

• The patient has an endocrine disease.

• The patient has a metabolic disease.

• The patient has a history of surgery.

• The patient is going to receive surgery of thyroid, intracranial procedure, joint replacement, major fracture.

• The patient's education history is shown less than 6 years of school.

• The patient is unable to complete neuropsychologic testing.

• The patient has vision dysfunction.

• The patient has auditory dysfunction.

• The operation going to be received is a laparoscopic surgery.

• The patient is hypersensitive to propofol or any other anesthetic agents.

• Involvement in the planning and conduct of the study

• Participation in another drug trial within 28 days prior enrolment into this study